Firalis is involved in several large scale projects for the qualification of biomarkers in various clinical applications and plays a central role as well in the EU Innovative Medicines Initiative-Joint Undertaking (IMI JU) Safer and Faster Evidence-based Translation of biomarkers, IMI SAFE-T consortium.

We are passionate about science and interact regularly with Health Authorities, in order to strictly follow EMA and FDA guidelines for the qualification of Firalis biomarker panels.


    Prof. Hüseyin FIRAT

    President & CEO

    He is a pediatrician and practiced as an associate professor in Paris University hospitals. After his PhD of Immunology at Pasteur Institute, he was accredited as research director, responsible of the Immunology Laboratory at Généthon.

    In 2002, he joined then the Biomarker Department of Novartis Pharma, where he headed global omics data analysis sections worldwide, served as senior Biomarker Expert in International Project Teams and was member of Novartis Pharma Innovation Team, Basel. His research activities generated several patented discoveries, based on which three biotech companies have been created. In 2007, he has been accredited as University Professor in France and founded Firalis SAS. He is the CEO and CSO of the company since then, in coordination with several business and scientific advisors, both external and in-house.

        Dr. Beatrice MOLAC

        Director of Intellectual Property and Regulatory Affairs

        Dr. Molac graduated from the “Ecole Nationale Supérieure de Chimie” in Mulhouse and completed her PhD at the University of Strasbourg.

        She was a European patent attorney at Sandoz AG and group Head of Pharma Patents Transplantation at Novartis AG until 2007. For 10 years she also headed the European Qualifying Examination Committee II and was a member of the European Board for the European Qualifying Examination, Munich. At Firalis, she is in charge of IP and Regulatory Affairs.